Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma
Laure Hirsch, Ronan Flippot, Bernard Escudier, et al.
Drugs (2020) Vol. 80, Iss. 12, pp. 1169-1181
Closed Access | Times Cited: 74

Showing 26-50 of 74 citing articles:

Intravital Imaging Identifies the VEGF–TXA2 Axis as a Critical Promoter of PGE2 Secretion from Tumor Cells and Immune Evasion
Yoshinobu Konishi, Hiroshi Ichise, Tetsuya Watabe, et al.
Cancer Research (2021) Vol. 81, Iss. 15, pp. 4124-4132
Open Access | Times Cited: 23
Checkpoint inhibitors in metastatic papillary renal cell carcinoma
Manon De Vries-Brilland, David F. McDermott, Cristina Suárez, et al.
Cancer Treatment Reviews (2021) Vol. 99, pp. 102228-102228
Closed Access | Times Cited: 21
Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations
Roberto Iacovelli, Chiara Ciccarese, Giuseppe Procopio, et al.
Cancer Treatment Reviews (2022) Vol. 105, pp. 102379-102379
Closed Access | Times Cited: 16
Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma
Yohei Sekino, Jun Teishima, Gangning Liang, et al.
International Journal of Urology (2022) Vol. 29, Iss. 12, pp. 1419-1428
Open Access | Times Cited: 16
Neoadjuvant Immune Checkpoint Inhibitors for Resectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Mei Zhao, Shanwen Chen, Conggui Li, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 600-600
Open Access | Times Cited: 9
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations
Lorena Incorvaia, Fernando Sabino Marques Monteiro, Francesco Massari, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 8
Open Access | Times Cited: 3
Circ-AFAP1 promote clear cell renal cell carcinoma growth and angiogenesis by the Circ-AFAP1/miR-374b-3p/VEGFA signaling axis
Yuxi Ou, Xiyu Dai, Xinan Chen, et al.
Cell Death Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 14
Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma
Annalisa Guida, Gwénaël Le Teuff, Carolina Guimarães Bonfim Alves, et al.
Oncotarget (2020) Vol. 11, Iss. 49, pp. 4582-4592
Open Access | Times Cited: 19
Immune checkpoint blockade in renal cell carcinoma
Phillip M. Rappold, Andrew W. Silagy, Ritesh R. Kotecha, et al.
Journal of Surgical Oncology (2021) Vol. 123, Iss. 3, pp. 739-750
Open Access | Times Cited: 17
Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab
Kousuke Ueda, Shigetaka Suekane, Hirofumi Kurose, et al.
Japanese Journal of Clinical Oncology (2022) Vol. 52, Iss. 5, pp. 479-485
Closed Access | Times Cited: 12
Circulating Levels of the Interferon-γ-Regulated Chemokines CXCL10/CXCL11, IL-6 and HGF Predict Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Antiangiogenic Therapy
Emilio Esteban, F. Navarro Expósito, Guillermo Crespo, et al.
Cancers (2021) Vol. 13, Iss. 11, pp. 2849-2849
Open Access | Times Cited: 15
Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinoma
Viktoria Stühler, Steffen Rausch, Moritz Maas, et al.
Expert Opinion on Biological Therapy (2021) Vol. 21, Iss. 9, pp. 1215-1226
Closed Access | Times Cited: 13
Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma
Hiroki Ishihara, Tsunenori Kondo, Kazutaka Nakamura, et al.
Japanese Journal of Clinical Oncology (2021) Vol. 51, Iss. 12, pp. 1751-1756
Closed Access | Times Cited: 13
DNA methylation in promoter region of immune related genes STAT3 and VEGFA and biochemical parameters change in muscle of Japanese flounder under acute hypoxia
Xiaohui Li, Binghua Liu, Jun Yang, et al.
Developmental & Comparative Immunology (2021) Vol. 129, pp. 104295-104295
Closed Access | Times Cited: 13
NISCAHN: a phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08)
Jérôme Fayette, Caroline Even, Laurence Digue, et al.
BMJ Oncology (2023) Vol. 2, Iss. 1, pp. e000065-e000065
Open Access | Times Cited: 5
The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma
Elie Rassy, Luigi Cerbone, Édouard Auclin, et al.
The Oncologist (2021) Vol. 26, Iss. 5, pp. 389-396
Open Access | Times Cited: 12
Research Progress for RNA Modifications in Physiological and Pathological Angiogenesis
Hui-Ming Chen, Hang Li, Meng-Xian Lin, et al.
Frontiers in Genetics (2022) Vol. 13
Open Access | Times Cited: 9
Avelumab: search for combinations of immune checkpoint inhibition with chemotherapy
Gerhard Hamilton
Expert Opinion on Biological Therapy (2020) Vol. 21, Iss. 3, pp. 311-322
Closed Access | Times Cited: 12
Integrated analysis of the relation to tumor immune microenvironment and predicted value of Stonin1 gene for immune checkpoint blockage and targeted treatment in kidney renal clear cell carcinoma
Axiu Zheng, Jianrong Bai, Yanping Ha, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 4
Biomarkers in renal cell carcinoma and their targeted therapies: a review
Shruti Gupta, Shamsher S. Kanwar
Exploration of Targeted Anti-tumor Therapy (2023), pp. 941-961
Open Access | Times Cited: 4
First-Line Treatments and Management of Metastatic Renal Cell Carcinoma Patients: An Italian Interdisciplinary Uro-Oncologic Group Algorithm
Francesco Bloise, Fiorella Manfredi, Luca Zatteri, et al.
Cells (2024) Vol. 13, Iss. 11, pp. 961-961
Open Access | Times Cited: 1
Activity of Systemic Treatments After Cabozantinib Failure in Advanced Metastatic Renal Cell Carcinoma
Luigi Cerbone, Vincenzo Di Nunno, L. Carril Ajuria, et al.
Clinical Genitourinary Cancer (2021) Vol. 20, Iss. 1, pp. 80-87
Closed Access | Times Cited: 9
First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?
Jacob J. Adashek, Joshua J. Breunig, Edwin M. Posadas, et al.
Drugs (2022) Vol. 82, Iss. 4, pp. 439-453
Closed Access | Times Cited: 6
Integrative analysis of TRPV family to prognosis and immune infiltration in renal clear cell carcinoma
Zixuan Gong, Jiaheng Xie, Liang Chen, et al.
Channels (2022) Vol. 16, Iss. 1, pp. 84-96
Open Access | Times Cited: 6
Identification of Immune and Hypoxia Risk Classifier to Estimate Immune Microenvironment and Prognosis in Cervical Cancer
Yujing Shi, Qing Gao, Zeyuan Liu, et al.
Journal of Oncology (2022) Vol. 2022, pp. 1-20
Open Access | Times Cited: 6

Scroll to top